- cafead   Aug 03, 2021 at 11:02: AM
via
article source
- Pfizer recently announced promising results for its oral protease inhibitor in post-exposure prophylaxis for COVID-19.
- The company estimates a potential addressable market for the therapy of up to hundreds of millions of patients if successful.
- Pfizer advanced the experimental drug into phase 2/3 testing in July and thinks it could file for EUA in Q4 if all goes well.
article source